Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,118.00INR
25 Apr 2018
Change (% chg)

Rs-32.15 (-1.50%)
Prev Close
Rs2,150.15
Open
Rs2,151.45
Day's High
Rs2,155.95
Day's Low
Rs2,113.00
Volume
288,899
Avg. Vol
548,313
52-wk High
Rs2,787.00
52-wk Low
Rs1,901.15

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs394,104.81
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.84

Financials

  REDY.NS Industry Sector
P/E (TTM): 32.79 30.95 32.74
EPS (TTM): 72.46 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK

* GETS ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR API MIRFIELD PLANT, UK Source text for Eikon: Further company coverage:

24 Apr 2018

BRIEF-Dr.Reddy's Laboratories Gets EIR From US FDA For API Cuernavaca Plant In Mexico

* SAYS GETS EIR FROM US FDA FOR API CUERNAVACA PLANT IN MEXICO Source text: https://bit.ly/2H9URmM Further company coverage:

10 Apr 2018

BUZZ-CY 2018 to be volatile for Indian stock markets - Citi

** Calendar year 2018 will be volatile for Indian stock markets, says Citi

09 Apr 2018

BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate

* CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE

02 Apr 2018

BRIEF-Dr.Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer

* CHIEF OPERATING OFFICER ABHIJIT MUKHERJEE TO RETIRE ON MARCH 31

29 Mar 2018

BRIEF-Dr.Reddy's Labs Gets Form 483 With 4 Observations For API Hyderabad Plant Audit

* SAYS AUDIT OF API HYDERABAD PLANT IN TELENGANA BY U.S. FDA COMPLETED ON MARCH 16

16 Mar 2018

BRIEF-Dr.Reddy's Laboratories Launches Levocetirizine Dihydrochloride Tablets USP, 5 Mg In U.S.

* ANNOUNCES LAUNCH OF LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS USP, 5 MG IN U.S. MARKET Source text - http://bit.ly/2FUOwea Further company coverage:

16 Mar 2018

BRIEF-India's Dr.Reddy's Laboratories Gets 5 Observations From U.S FDA For API Unit At Hyderabad ‍​

* U.S FDA ISSUES FORM 483 WITH 5 OBSERVATIONS FOR API UNIT AT HYDERABAD ‍​ Source text - http://bit.ly/2IehGDn Further company coverage:

09 Mar 2018

BRIEF-Dr.Reddy's Laboratories Says Amended Complaint w.r.t U.S. Class Action Lawsuit Filed

* W.R.T U.S. CLASS ACTION LAWSUIT, AMENDED COMPLAINT FILED BY PLAINTIFF WHERE CHAIRMAN, COO AND U.S. UNIT ADDED AS DEFENDANTS Source text - http://bit.ly/2CvdcnN Further company coverage:

19 Feb 2018

BRIEF-Dr.Reddy's Lab Announces Launch Of Tetrabenazine Tablets In U.S. Market

* SAYS ANNOUNCEMENT OF LAUNCH OF TETRABENAZINE TABLETS IN U.S. MARKET Source text - http://bit.ly/2GH4t5d Further company coverage:

02 Feb 2018

Earnings vs. Estimates